McMasterLogo_New-2017-300x165
Back
Clinician Article

Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.



  • Khatcheressian JL
  • Hurley P
  • Bantug E
  • Esserman LJ
  • Grunfeld E
  • Halberg F, et al.
J Clin Oncol. 2013 Mar 1;31(7):961-5. doi: 10.1200/JCO.2012.45.9859. Epub 2012 Nov 5. (Review)
PMID: 23129741
Read abstract Read evidence summary Read full text
Disciplines
  • Oncology - Breast
    Relevance - 7/7
    Newsworthiness - 5/7

Abstract

PURPOSE: To provide recommendations on the follow-up and management of patients with breast cancer who have completed primary therapy with curative intent.

METHODS: To update the 2006 guideline of the American Society of Clinical Oncology (ASCO), a systematic review of the literature published from March 2006 through March 2012 was completed using MEDLINE and the Cochrane Collaboration Library. An Update Committee reviewed the evidence to determine whether the recommendations were in need of updating.

RESULTS: There were 14 new publications that met inclusion criteria: nine systematic reviews (three included meta-analyses) and five randomized controlled trials. After its review and analysis of the evidence, the Update Committee concluded that no revisions to the existing ASCO recommendations were warranted.

RECOMMENDATIONS: Regular history, physical examination, and mammography are recommended for breast cancer follow-up. Physical examinations should be performed every 3 to 6 months for the first 3 years, every 6 to 12 months for years 4 and 5, and annually thereafter. For women who have undergone breast-conserving surgery, a post-treatment mammogram should be obtained 1 year after the initial mammogram and at least 6 months after completion of radiation therapy. Thereafter, unless otherwise indicated, a yearly mammographic evaluation should be performed. The use of complete blood counts, chemistry panels, bone scans, chest radiographs, liver ultrasounds, pelvic ultrasounds, computed tomography scans, [(18)F]fluorodeoxyglucose-positron emission tomography scans, magnetic resonance imaging, and/or tumor markers (carcinoembryonic antigen, CA 15-3, and CA 27.29) is not recommended for routine follow-up in an otherwise asymptomatic patient with no specific findings on clinical examination.


Clinical Comments

Oncology - Breast

A short article examining research evidence since the last guideline update (2006). It focuses particularly in coordination of care, but concludes that there was insufficient evidence to change any of the 2006 guidelines.

Oncology - Breast

Directly and highly relevant confirmation of this information especially when health care costs are increasingly considered. Programs that aim to ensure patients safety, efficacy and confidence through education are more important than tests repeated exhaustion.

Register for free access to all Professional content

Register